All three PET agents demonstrate roughly equivalent abilities to detect brain amyloid, a new analysis finds.
Spinal taps have a bad rap. Are headaches really all that common afterwards, and are there ways to prevent them?
Early data suggest that the T807/AV1451 signal relates to cerebrospinal biomarkers of Alzheimer’s, intensifies by up to 10 percent a year, and might nail diagnoses beyond typical AD.
Cognitively normal people with levels of CSF Aβ42 near the cutoff point associated with amyloid pathology are likely to cross that threshold within three years.
Two new open-access journals will cover specialized areas of Alzheimer’s research.
Qualification could follow, but only if trial sponsors fork over fresh data.
The highs and lows of cerebrospinal fluid Aβ and PET amyloid imaging don't necessarily agree.
Deep brain stimulation helps many people with Parkinson’s, but how it does so remains a mystery. A new study suggests it normalizes brain rhythms.
Several different striatal markers may help researchers track early deterioration in Huntington's and Parkinson’s diseases.
Scientists find neurodegenerative proteins squirreled away in the skin cells of patients. Could this present an untapped source of biomarkers?
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.
Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Scientists struggle to understand neurodegeneration in the SNAP syndrome.
Postmortem pathology confirms that some people who were diagnosed with AD during life had no appreciable amyloid in the brain, leaving researchers to puzzle over what caused their cognitive decline.